Background
UniProt:P62937 encodes a protein involved in fundamental cellular functions, including regulation of protein synthesis and cell cycle control, processes often dysregulated in cancer. In urothelial carcinoma, a malignancy of the urinary tract epithelium with limited targeted therapies, identifying novel molecular targets is critical. The expression profile of UniProt:P62937 in urothelial carcinoma tissues suggests a potential role in tumor biology, although its specific involvement remains uncharacterized. As such, UniProt:P62937 represents a putative target that warrants further experimental validation to clarify its relevance in urothelial carcinoma pathogenesis.
Data-mining rationale
This candidate was identified through a systematic cross-referencing of reviewed human protein entries in UniProt associated with "urothelial carcinoma" against 74 microarray datasets from the NCBI Gene Expression Omnibus (GEO). UniProt:P62937 appeared in multiple expression profiling studies, including datasets GDS:200292216, GDS:200245118, GDS:200253531, GDS:200201395, and GDS:200181962, which collectively examine gene expression differences between urothelial carcinoma and normal tissue or among tumor subtypes. This integrative data-mining approach highlights UniProt:P62937 as a putative target based on its recurrent differential expression patterns in urothelial carcinoma samples.
Why prior analyses may have missed this
Many of the GEO datasets analyzed were generated before the adoption of modern empirical-Bayes statistical methods such as limma, which improve the detection of differentially expressed genes by stabilizing variance estimates across genes. Earlier analyses often lacked rigorous multiple-testing correction strategies like the Benjamini-Hochberg false discovery rate (FDR), which may have led to false negatives or positives. Consequently, the significance of UniProt:P62937’s differential expression in urothelial carcinoma may have been underestimated or overlooked. Re-analysis of these datasets using updated statistical frameworks could clarify the gene’s role and strengthen its candidacy as a target.
Reasoning for further validation
To establish UniProt:P62937 as a putative target in urothelial carcinoma, several experimental steps are recommended. First, re-analyzing the matched GEO datasets with limma and Benjamini-Hochberg FDR control will provide a statistically robust assessment of differential expression. Second, validation of top differentially expressed genes, including UniProt:P62937, by quantitative PCR in independent urothelial carcinoma cohorts will confirm reproducibility. Third, evaluating tissue specificity using resources such as GTEx and the Human Protein Atlas will determine expression patterns in normal and malignant urothelial tissues. Fourth, pathway analysis through STRING or OmniPath can contextualize UniProt:P62937 within relevant signaling networks, potentially elucidating mechanisms of action. Finally, if validated, assessing druggability via databases like DGIdb and ChEMBL will inform the feasibility of therapeutic targeting. These investigations will help clarify the biological and translational relevance of UniProt:P62937 in urothelial carcinoma.